Medifast, Inc.
MED
$12.92
-$0.205-1.56%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.47% | -43.80% | -44.64% | -43.90% | -41.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.47% | -43.80% | -44.64% | -43.90% | -41.32% |
| Cost of Revenue | -41.14% | -46.71% | -47.72% | -48.15% | -44.36% |
| Gross Profit | -38.85% | -42.69% | -43.45% | -42.23% | -40.12% |
| SG&A Expenses | -29.39% | -32.19% | -32.34% | -33.35% | -36.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.71% | -36.60% | -37.14% | -38.03% | -38.78% |
| Operating Income | -107.82% | -97.72% | -93.33% | -81.50% | -58.64% |
| Income Before Tax | -108.35% | -97.06% | -91.87% | -78.41% | -52.28% |
| Income Tax Expenses | -101.43% | -94.23% | -84.16% | -80.01% | -52.55% |
| Earnings from Continuing Operations | -110.32% | -97.90% | -93.89% | -77.94% | -52.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.32% | -97.90% | -93.89% | -77.94% | -52.20% |
| EBIT | -107.82% | -97.72% | -93.33% | -81.50% | -58.64% |
| EBITDA | -86.72% | -84.45% | -88.22% | -76.01% | -54.47% |
| EPS Basic | -110.28% | -97.89% | -93.88% | -77.89% | -51.59% |
| Normalized Basic EPS | -108.32% | -97.05% | -92.46% | -79.80% | -54.75% |
| EPS Diluted | -110.50% | -98.02% | -94.02% | -77.91% | -51.46% |
| Normalized Diluted EPS | -108.36% | -97.09% | -92.49% | -79.80% | -54.62% |
| Average Basic Shares Outstanding | 0.41% | 0.42% | 0.27% | 0.00% | -1.16% |
| Average Diluted Shares Outstanding | 0.22% | 0.38% | 0.13% | -0.20% | -1.41% |
| Dividend Per Share | -- | -- | -100.00% | -74.92% | -49.77% |
| Payout Ratio | -1.04% | -0.53% | 3.19% | 1.28% | 0.54% |